Targeted Treatment Considerations in EGFR-Mutated NSCLC
Treatment for EGFR-mutated non–small cell lung cancer (NSCLC) may include chemotherapy, radiation therapy, immunotherapy, and targeted antibodies, as well as surgical resection, with EGFR tyrosine kinase inhibitors (TKIs) playing an increasingly important role. First-, second-, and third-generation EGFR TKIs are currently U.S. Food and Drug Administration–approved and available for eligible patients. Clearly, there is no shortage of therapeutic strategies; the clinical challenge thus lies in selecting the most appropriate option for each individual patient.
In this new, informative, three-part video roundtable from JNCCN–Journal of the National Comprehensive Cancer Network, Sandip Patel, MD, and his expert colleagues Gregory Riely, MD, PhD, and Jessica Bauman, MD, guide viewers through therapeutic decision-making in clinical cases in the first-line metastatic, advanced nonresectable, and adjuvant settings of EGFR-mutated NSCLC, sharing key trial data and their own professional insights. With an eye on future outcomes, the faculty conclude each case presentation with a comprehensive discussion of unresolved clinical questions and pertinent considerations.
